Clinical trials: Dexamethasone Administration
Multiple Myeloma
Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma
This will be a multi-center, open label, expanded treatment protocol of panobinostat, bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
- Trial name
- NCT02204553
- Testing
- Panobinostat
- Where
- 27 sites in United States
- Sponsor
- Novartis Pharmaceuticals
Plasma Cell Myeloma Recurrent
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
This will be randomized, multicenter, Phase 3, open-label study evaluating subcutaneous (SC) vs intravenous (IV) administration of isatuximab in combination with pomalidomide and dexamethasone (Pd) in RRMM patients (study…
- Trial name
- IRAKLIA (NCT05405166)
- Testing
- Isatuximab IV, Isatuximab SC, Dexamethasone
- Where
- 128 sites in United States, Argentina and 19 more
- Volunteers
- 531 people
- Sponsor
- Sanofi
Multiple Myeloma
Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma
To provide pomalidomide access to relapsed/refractory multiple myeloma subjects with a likelihood of benefit from the pomalidomide treatment while the medication is not commercially available
- Trial name
- PEXIUS (NCT01632826)
- Testing
- Pomalidomide
- Where
- 42 sites in United States, Canada
- Sponsor
- Celgene
Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
This randomized phase III trial is studying APF530 and dexamethasone to see how well they work compared with palonosetron and dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for cancer.
- Trial name
- NCT00343460
- Testing
- APF530, dexamethasone, Palonosetron Hydrochloride
- Where
- 52 sites in United States
- Volunteers
- 1,428 people
- Sponsor
- Heron Therapeutics
Multiple Myeloma
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
The purpose of this study is to compare the efficacy of lenalidomide and low dose dexamethasone with pembrolizumab (MK-3475) to that of lenalidomide and low dose dexamethasone without pembrolizumab in terms of progression-free…
- Trial name
- NCT02579863
- Testing
- Pembrolizumab, Lenalidomide, Dexamethasone
- Volunteers
- 310 people
- Sponsor
- Merck Sharp & Dohme LLC
Relapsed/Refractory Multiple Myeloma
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of etentamig (ABBV-383) when co-administered…
- Trial name
- NCT05259839
- Testing
- Etentamig, Dexamethasone, Lenalidomide
- Where
- 49 sites in United States, Australia and 5 more
- Volunteers
- 283 people
- Sponsor
- AbbVie
Relapsed Multiple Myeloma, Refractory Multiple Myeloma
Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.
Compare carfizomib, dexamethasone, and daratumumab (KdD) to Carfilzomib and dexamethasone (Kd) in terms of progression free survival (PFS) in participants with multiple myeloma who have relapsed after 1 to 3 prior therapies.
- Trial name
- CANDOR (NCT03158688)
- Testing
- Dexamethasone, Daratumumab, Carfilzomib
- Where
- 113 sites in United States, Australia and 17 more
- Volunteers
- 466 people
- Sponsor
- Amgen
Dry Eye
The DEPOT Study (Dry Eye Prescription Options for Therapy)
Assessing DEXTENZA efficacy and safety when placed within the lower eyelid canaliculus for dry eye flares in comparison to topical loteprednol suspension.
- Trial name
- NCT04911361
- Testing
- Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Research Insight LLC
Relapsed/Refractory Multiple Myeloma
A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
The main purpose of this study is to measure the efficacy (Myeloma response) of subcutaneous (SC) isatuximab treatment in combination with carfilzomib and dexamethasone in adult participants with RRMM having received 1 to 3 prior…
- Trial name
- IZALCO (NCT05704049)
- Testing
- Isatuximab, Carfilzomib, Dexamethasone
- Where
- 23 sites in Australia, Brazil and 5 more
- Volunteers
- 118 people
- Sponsor
- Sanofi
Idiopathic Thrombocytopenic Purpura
A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)
This study will compare the efficacy, safety, and pharmacokinetics of standard treatment versus standard treatment plus MabThera in patients with ITP.
- Trial name
- NCT00770562
- Testing
- rituximab, Dexamethasone
- Where
- 22 sites in Italy
- Volunteers
- 103 people
- Sponsor
- Hoffmann-La Roche
Plasma Cell Myeloma
SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients
Primary Objectives: To determine the maximum tolerated dose of SAR650984 (isatuximab) with lenalidomide and dexamethasone (LD) in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT01749969
- Testing
- isatuximab SAR650984, lenalidomide, dexamethasone
- Where
- 5 sites in United States
- Volunteers
- 57 people
- Sponsor
- Sanofi
Multiple Myeloma
CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma
The purpose of the study is to select the dose regimen of CDC-501 that provides the most promising evidence of efficacy.
- Trial name
- NCT00044018
- Testing
- CDC-501
- Where
- 4 sites in United States
- Volunteers
- 102 people
- Sponsor
- Celgene
Multiple Myeloma
Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma
The objective of this study is to show that thalidomide at a dose of 100 mg/d (with remedial treatment with dexamethasone if a progression occurs) is equivalent in terms of efficacy with thalidomide at 400 mg/d (with remedial…
- Trial name
- NCT00657488
- Testing
- Thalidomide
- Where
- 49 sites in Belgium, France
- Volunteers
- 400 people
- Sponsor
- Celgene
Allergic Conjunctivitis
Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis
The purpose of this study was to evaluate the efficacy of Maxidex and Patanol compared to placebo in patients with allergic conjunctivitis when exposed to controlled allergen levels in an Environmental Exposure Chamber (EEC).
- Trial name
- NCT01119287
- Testing
- Dexamethasone 0.1% ophthalmic suspension, Olopatadine hydrochloride 0.1% ophthalmic solution
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Alcon Research
Diabetes Mellitus
Intraoperative Dexamethasone and Its Effect on Hyperglycemia
To study the effect of intra-operative dexamethasone on the management of post-operative blood sugar in diabetic patients.
- Trial name
- NCT03646916
- Testing
- Dexamethasone, No dexamethasone
- Where
- United States
- Sponsor
- Ascension Health
Multiple Myeloma
Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma
The purpose of this study is to determine the best dose of ACY-1215 in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.
- Trial name
- NCT01583283
- Testing
- ACY-1215, lenalidomide, Dexamethasone
- Where
- 5 sites in United States
- Volunteers
- 38 people
- Sponsor
- Celgene
Blepharoconjunctivitis
Comparative Study of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone to Treat Subjects With Blepharoconjunctivitis
The purpose of this study is to determine if AzaSite Plus is effective and safe for the treatment of blepharoconjunctivitis compared to AzaSite alone and Dexamethasone alone.
- Trial name
- NCT00754949
- Testing
- 1% Azithromycin and 0.1% Dexamethasone, 1% Azithromycin, 0.1% Dexamethasone
- Sponsor
- Sun Pharmaceutical Industries Limited
Multiple Myeloma
A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma
The main aim is to show that long-term use of ixazomib can improve symptoms of multiple myeloma and provide an effective long-term alternative treatment.
- Trial name
- US MM-7 (NCT05183139)
- Testing
- Ixazomib, Pomalidomide, Lenalidomide
- Sponsor
- Takeda
Multiple Myeloma in Relapse, Refractory Multiple Myeloma
TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
This trial is a multi-center, single-arm phase 2 study to evaluate the efficacy and safety of TJ202 combined with dexamethasone in subjects with relapsed or refractory multiple myeloma (RRMM) who received at least 2 prior lines…
- Trial name
- NCT03860038
- Testing
- TJ202 and Dexamethasone
- Where
- 18 sites in China, Taiwan
- Volunteers
- 113 people
- Sponsor
- TJ Biopharma Co., Ltd.
Relapsed or Refractory Systemic Light Chain Amyloidosis
Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
The purpose of this study is to provide continued access of ixazomib and/or other study medications and to continue collecting relevant safety data to monitor participant's safety, determine whether dexamethasone plus IXAZOMIB…
- Trial name
- NCT01659658
- Testing
- IXAZOMIB, Dexamethasone, Melphalan
- Where
- 66 sites in United States, Australia and 13 more
- Volunteers
- 177 people
- Sponsor
- Millennium Pharmaceuticals, Inc.